Evidence-based Medicine
Opinion | Is it time for Evidence-Based Medicine 2.0?
21 Oct, 2021 | 09:59h | UTCIs it time for Evidence-Based Medicine 2.0? – Centre for Evidence-Based Medicine
Opinion | Understanding of research results, evidence summaries and their applicability—not critical appraisal—are core skills of medical curriculum.
21 Oct, 2021 | 09:57h | UTC
Commentary on Twitter
Is the critical appraisal of individual studies a core skill for clinicians? @KariTikkinen and @EBCPMcMaster argue that there are more important things for them to learn in order to apply #EBM in real life.
A thought-provoking piece in @BMJ_EBM 👌https://t.co/f6KvsRpHOw pic.twitter.com/FOf5ywT1bf
— Lucas Morin (@lucasmorin_eolc) October 20, 2021
Users’ guides to the medical literature: how to interpret and use a clinical practice guideline or recommendation.
20 Oct, 2021 | 10:09h | UTCHow to Interpret and Use a Clinical Practice Guideline or Recommendation: Users’ Guides to the Medical Literature – JAMA (free for a limited period)
Author Interview: How to Interpret and Use a Clinical Practice Guideline
Long-term consequences of the misuse of ivermectin data.
19 Oct, 2021 | 09:56h | UTCLong-term consequences of the misuse of ivermectin data – The Lancet Infectious Diseases
Related:
Ivermectin: How false science created a Covid ‘miracle’ drug.
Fraudulent ivermectin studies open up new battleground between science and misinformation.
The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable.
Ivermectin: Cochrane’s most talked about review so far, ever. Why?
Flawed ivermectin preprint highlights challenges of COVID drug studies.
Systematic review: no evidence to support the use of Ivermectin for treating or preventing COVID-19.
Why was a major study on ivermectin for covid-19 just retracted?
RCT: Ivermectin does not prevent hospitalizations in patients with COVID-19.
RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19
Commentary on Twitter
Ivermectin's data for Covid, checkered with inconsistencies, small/low quality clinical trials, and fraud, have long-term consequences for the drug's established and essential useshttps://t.co/NG6vpej8GP @TheLancetInfDis pic.twitter.com/Oz0FxUJetK
— Eric Topol (@EricTopol) October 18, 2021
Opinion | Multi-cancer screening tests: communicating about risks should be prioritized.
19 Oct, 2021 | 08:49h | UTC
Viewpoint: Surgical overtreatment and shared decision-making—the limits of choice. – “Payment models further incentivize surgical intervention. Fee-for-service payment plans reward surgeons for operating, not for ensuring that surgery is right for a patient”.
17 Oct, 2021 | 21:17h | UTCSurgical Overtreatment and Shared Decision-making—The Limits of Choice – JAMA Surgery (free for a limited period)
Commentary on Twitter
“Adjusting payment models to mitigate financial incentives..to overtreat is a start. However..greater focus should be given to the myriad other causes of overtreatment,” such as triggers of care cascades, write Clapp, Schwarze & @LeeAFleisher. https://t.co/f4mPsnxyVB
— Ben Harder #BlackLivesMatter (@benharder) October 14, 2021
Editorial: Covid-19 treatments and vaccines must be evaluated in pregnancy.
15 Oct, 2021 | 02:41h | UTCCovid-19 treatments and vaccines must be evaluated in pregnancy – The BMJ
Related:
Study shows high effectiveness of the Pfizer mRNA COVID-19 vaccine in pregnancy.
5 Crucial Things to Know About COVID-19 Vaccines and Pregnancy.
CDC Guidance: Pregnant people should be vaccinated against COVID-19.
Cohort study: Pfizer/BioNTech COVID vaccine associated with 78% lower risk of Covid-19 in pregnancy.
Commentary on Twitter
Inconsistent messaging from authorities, driven by lack of trial data, has increased covid-19 vaccine hesitancy among pregnant women@DrAllyah and colleagues argue that pregnant women should be included in drug and vaccine development from the outsethttps://t.co/P3v1ouk8tQ
— The BMJ (@bmj_latest) October 14, 2021
Systematic Review: “Formula milk trials have a high risk of bias, almost always report favorable conclusions, lack transparency, and selectively report findings”.
15 Oct, 2021 | 02:25h | UTCNews release: Formula milk trials are not reliable, warn researchers – Imperial College London
Original study: Conduct and reporting of formula milk trials: systematic review – The BMJ
How to be a good science communicator.
14 Oct, 2021 | 10:13h | UTCHow to be a good science communicator – Nature Medicine
Commentary on Twitter
During the COVID-19 pandemic, the public have turned to scientists and doctors for vital information. But science communication is a skill in itself, so we asked the experts to share their tips.
Feature from @polkajunctionhttps://t.co/eK2HYqs67m
— Nature Medicine (@NatureMedicine) October 13, 2021
Podcast with Dr Walter Willett: CardioNutrition – Why are findings from prospective, epidemiologic cohort studies important in informing dietary recommendations?
14 Oct, 2021 | 09:49h | UTC
Commentary on Twitter
In this episode of CardioNutrition, @DrOstfeld and Dr. Walter Willett discuss why findings from prospective, epidemiologic cohort studies are important in informing dietary recommendations. Learn more here: https://t.co/IfIgauGhV9 #cvPrev #cvLipids pic.twitter.com/flet8ZTwFe
— American College of Cardiology (@ACCinTouch) October 8, 2021
Editorial: How to develop a quality research article and avoid a journal desk rejection.
13 Oct, 2021 | 01:18h | UTCEditorial: How to develop a quality research article and avoid a journal desk rejection – International Journal of Information Management (free for a limited period)
Bioethics | The Trolley Problem and Vaccinating Young People Against COVID-19.
10 Oct, 2021 | 21:50h | UTCThe Trolley Problem and Vaccinating Young People Against COVID-19 – Science-Based Medicine
Ivermectin: How false science created a Covid ‘miracle’ drug.
8 Oct, 2021 | 10:24h | UTCIvermectin: How false science created a Covid ‘miracle’ drug – BBC
Commentary on Twitter
Scientists evaluating ivermectin data for #COVID19
"had not found 'a single clinical trial' claiming to show that ivermectin prevented Covid deaths that did not contain 'either obvious signs of fabrication or errors so critical they invalidate the study'." https://t.co/Xndr6Q5LaS— Isaac Bogoch (@BogochIsaac) October 7, 2021
GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings.
7 Oct, 2021 | 10:11h | UTC
Key concepts in clinical epidemiology: Stepped wedge trials.
7 Oct, 2021 | 10:10h | UTCKey concepts in clinical epidemiology: Stepped wedge trials – Journal of Clinical Epidemiology
Evaluating agreement between bodies of evidence from randomized controlled trials and cohort studies in nutrition research: meta-epidemiological study.
5 Oct, 2021 | 08:48h | UTC
Commentary on Twitter
The difference in results between RCTs and cohort studies in nutrition research was small, finds study.
However, with some substantial statistical heterogeneity in cohort studies, differences or potential bias cannot be excluded, say @LSchwingshackl et alhttps://t.co/dyUqhn87V0
— The BMJ (@bmj_latest) September 17, 2021
Guide to Statistics and Methods: Interim Analyses During Group Sequential Clinical Trials.
3 Oct, 2021 | 22:30h | UTCInterim Analyses During Group Sequential Clinical Trials – JAMA (free for a limited period)
Publishers unite to tackle doctored images in research papers.
30 Sep, 2021 | 10:12h | UTCPublishers unite to tackle doctored images in research papers – Nature
M-A: Magnitude of the placebo response across treatment modalities used for treatment-resistant depression in adults.
29 Sep, 2021 | 10:04h | UTCInvited Commentary: Treatment-Resistant Depression—Resistant to Placebos as Well? – JAMA Network Open
Commentaries on Twitter
This systematic review and meta-analysis found that in studies of patients with treatment-resistant depression, the placebo effect was large and consistent despite the modality use. https://t.co/U6efJo7rJ8
— JAMA Network Open (@JAMANetworkOpen) September 24, 2021
Important systematic review study: The placebo effect in clinical trials of depression, even if treatment-resistant, is huge!
Magnitude of the Placebo Response Across Treatment-Resistant Depression in Adults https://t.co/ey2hIpE61r via @JAMANetworkOpen part of @JAMANetwork
— Yasser Ad-Dab'bagh (@yasseraddabbagh) September 25, 2021
Question
Why does research on 'treatment resistance' have such high placebo response?3 Answers
1)Research patients arent nearly as sick as patients in clinical practice
2)Research patients get much more attention than clinical patients
3)Research raises very high expectations https://t.co/f8CyTpKofV— Allen Frances (@AllenFrancesMD) September 26, 2021
(thread – click for more)
The paradox of "treatment resistance" in psychiatry that doesn't seem to generate much discussion: if the depression is so treatment resistant that we are considering things like invasive brain stimulation, how come it responds to "placebo" so robustly?/1https://t.co/oQOBPXtVXO
— Awais Aftab (@awaisaftab) September 26, 2021
Editorial: It is time for consensus on ‘consensus statements’?
29 Sep, 2021 | 10:01h | UTCIt is time for consensus on ‘consensus statements’? – British Journal of Sports Medicine
Commentary on Twitter
Is it time for a #consensus on "consensus statements"?🤔
This #OpenAccess article looks into if some of them deserve their prestige, bias in methods of development, and proposes future steps to improve their quality⬇️https://t.co/uZUObQX6FW pic.twitter.com/lF62IUm49D
— British Journal of Sports Medicine (BJSM) (@BJSM_BMJ) September 25, 2021
Opinion | ‘Health equity tourists’: How white scholars are colonizing research on health disparities.
29 Sep, 2021 | 09:53h | UTC‘Health equity tourists’: How white scholars are colonizing research on health disparities – STAT
Opinion: Paying participants isn’t the way to improve clinical trial recruitment.
29 Sep, 2021 | 09:54h | UTCPaying participants isn’t the way to improve clinical trial recruitment – STAT
Bayesian interpretation of p values in clinical trials.
28 Sep, 2021 | 09:01h | UTCBayesian interpretation of p values in clinical trials – BMJ Evidence-Based Medicine
Commentary on Twitter
How to interpret p values in clinical trials from a Bayesian perspective? A guideline with examples by John Ferguson#OpenAccess
📰https://t.co/cDMpSG5K9B pic.twitter.com/83wzpSTerV— BMJ Evidence-Based Medicine (@BMJ_EBM) September 26, 2021
New guidelines to improve reporting standards of studies that investigate causal mechanisms.
28 Sep, 2021 | 09:00h | UTCNews release: New guidelines to improve reporting standards of studies that investigate causal mechanisms – University of Oxford
Original article: A Guideline for Reporting Mediation Analyses of Randomized Trials and Observational Studies: The AGReMA Statement – JAMA (free for a limited period)
Commentary: Reporting Findings From Mediation Analyses – JAMA (free for a limited period)
Commentary on Twitter (thread – click for more)
✨NEW✨ "A Guideline for Reporting Mediation Analyses of Randomized Trials and Observational Studies – The AGReMA statement" is now available @JAMA_current pic.twitter.com/nrt6grhomP
— Hopin Lee (@hopinlee) September 21, 2021
Beware survivorship bias in advice on science careers – “For objective careers advice, talk to those who left science as well as those who stayed”.
28 Sep, 2021 | 08:59h | UTCBeware survivorship bias in advice on science careers – Nature